Our study might have a clinical practice impact, in that our novel analysis clinically has the potential to become a new classification method of HER2 ITH and predict prognosis in patients with HER2-positive gastric cancer as well as breast cancer, as a discriminative, inexpensive, and easy-to-perform method. This evidence concerns the gene ERBB2 and breast carcinoma.